Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week High – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $27.09 and last traded at $26.54, with a volume of 148021 shares trading hands. The stock had previously closed at $25.97.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. TD Cowen assumed coverage on Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating on the stock. Finally, Morgan Stanley reduced their target price on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $34.42.

Dyne Therapeutics Trading Down 0.2%

The stock’s fifty day simple moving average is $21.86 and its 200-day simple moving average is $19.13. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The firm has a market cap of $4.82 billion, a PE ratio of -7.82 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current year.

Insider Activity

In other news, Director Jason P. Rhodes sold 297,211 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total value of $6,913,127.86. Following the completion of the sale, the director directly owned 2,962 shares in the company, valued at $68,896.12. The trade was a 99.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner acquired 2,000 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was purchased at an average price of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the acquisition, the director owned 24,500 shares in the company, valued at $415,030. The trade was a 8.89% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 9,000 shares of company stock worth $156,800 and sold 1,558,819 shares worth $34,385,234. Company insiders own 9.46% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares in the last quarter. Vanguard Group Inc. boosted its position in Dyne Therapeutics by 14.9% during the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after acquiring an additional 1,455,151 shares during the last quarter. State Street Corp boosted its position in Dyne Therapeutics by 27.0% during the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after acquiring an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after acquiring an additional 1,618,000 shares in the last quarter. Finally, Orbis Allan Gray Ltd purchased a new stake in Dyne Therapeutics during the 4th quarter valued at about $93,926,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.